Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Séverine Vermeire, Ann Gils et al.|Clinical Gastroenterology and Hepatology|2018Cited by 158
Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Marc Ferrante, Erwin Dreesen et al.|Journal of Crohn s and Colitis|2019Cited by 123
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn’s Disease Who Failed Biologic Therapies: A National Cohort StudyClaire Liefferinckx, Séverine Vermeire, Bram Verstockt et al.|Journal of Crohn s and Colitis|2019Cited by 121
Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD PatientsBram Verstockt, Marc Ferrante, Evelien Mertens et al.|Journal of Crohn s and Colitis|2019Cited by 38
Screening Failure in a Large Clinical Trial Centre for Inflammatory Bowel Diseases: Rates, Causes, and OutcomesAn Outtier, Liese Gijbels, Maja Noman et al.|Inflammatory Bowel Diseases|2022Cited by 9